Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vanda Pharmaceuticals Inc.VNDA · Entity 5861 | Director | June 04, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vanda Pharmaceuticals Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 164,950 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 41,600 · Balance 164,950 F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 4, 2027, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 4, 2027, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 8, 2026 20:23 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 41,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-261811 · ownership.xml · nonDerivative · entry 1 Chrousos Phaedra · CIK 0001774518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,950 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 4, 2027, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 21:35 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 59,225 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083889 · ownership.xml · nonDerivative · entry 1 Chrousos Phaedra · CIK 0001774518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,350 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 5, 2026, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| May 22, 2024 Filed May 24, 2024 20:43 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (right to buy) · Derivative | 40,202 | $0.00 Strike: $5.14 | $0.00 |
DisclosureSEC source: 0000950170-24-064669 · ownership.xml · derivative · entry 2 Chrousos Phaedra · CIK 0001774518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,202 Underlying: Common Stock · 40,202 shares Expires 2034-05-21 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 100% of the option shares on May 22, 2025, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| May 22, 2024 Filed May 24, 2024 20:43 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 21,887 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-064669 · ownership.xml · nonDerivative · entry 1 Chrousos Phaedra · CIK 0001774518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,125 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 22, 2025, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:17 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 33,960 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001209191-23-036275 · doc4.xml · derivative · entry 2 Chrousos Phaedra · CIK 0001774518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,960 Underlying: Common Stock · 33,960 shares Expires 2033-06-07 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 100% of the option shares on June 8, 2024, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:17 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 17,307 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-036275 · doc4.xml · nonDerivative · entry 1 Chrousos Phaedra · CIK 0001774518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,238 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 8, 2024, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 20:53 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 24,707 | $0.00 Strike: $9.37 | $0.00 |
DisclosureSEC source: 0001209191-22-038446 · doc4.xml · derivative · entry 2 Chrousos Phaedra · CIK 0001774518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,707 Underlying: Common Stock · 24,707 shares Expires 2032-06-15 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 100% of the option shares on June 16, 2023, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 20:53 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 12,006 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-038446 · doc4.xml · nonDerivative · entry 1 Chrousos Phaedra · CIK 0001774518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,931 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 16, 2023, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 14, 2021 Filed Jun 15, 2021 20:42 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 2,075 | $19.34 | $40,132.16 |
DisclosureSEC source: 0001209191-21-040615 · doc4.xml · nonDerivative · entry 1 Chrousos Phaedra · CIK 0001774518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,925 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.33 to $19.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:34 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $19.21 | $0.00 |
DisclosureSEC source: 0001209191-21-040236 · doc4.xml · derivative · entry 2 Chrousos Phaedra · CIK 0001774518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-09 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 100% of the option shares on June 10, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:34 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040236 · doc4.xml · nonDerivative · entry 1 Chrousos Phaedra · CIK 0001774518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 10, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 23:10 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $10.57 | $0.00 |
DisclosureSEC source: 0001209191-20-036780 · doc4.xml · derivative · entry 2 Chrousos Phaedra · CIK 0001774518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-10 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 100% of the option shares on June 11, 2021, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 23:10 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036780 · doc4.xml · nonDerivative · entry 1 Chrousos Phaedra · CIK 0001774518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 11, 2021, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 21:01 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0001209191-19-037409 · doc4.xml · derivative · entry 2 Chrousos Phaedra · CIK 0001774518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-12 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 100% of the option shares on June 13, 2020, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 21:01 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-037409 · doc4.xml · nonDerivative · entry 1 Chrousos Phaedra · CIK 0001774518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 13, 2020, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| April 23, 2019 Filed Apr 24, 2019 21:34 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $17.31 | $0.00 |
DisclosureSEC source: 0001209191-19-025783 · doc4.xml · derivative · entry 1 Chrousos Phaedra · CIK 0001774518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-04-22 F1 · derivative.exercise_date: The option vests with respect to 25% of the underlying shares when the Reporting Person completes 12 months of continuous service following the date of grant, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.